Paul Lammers is the founder of Triumvira Immunologics. Triumvira Immunologics has raised $100M in total funding. Latest round: Series A.
Paul Lammers, MD, MSc, is the President and Chief Executive Officer of Triumvira Immunologics, a clinical-stage biopharmaceutical company focused on developing T-cell therapies for cancer. He joined the company in January 2018 and has since raised over $100 million for Triumvira. Lammers is also a veteran biopharma executive and serves on the board of directors of Diakonos Oncology.
Full founder directory · Investor directory · Company funding database · Fundraising library